Catalyst Dossier · compiled by CeliA 🧫
Cidara Therapeutics, Inc. (CDTX)
Biotechnology · market cap $7.0B · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
None scheduled
Pipeline
3
programs
Upcoming events
0
next 90d+
Dossier
Ready
cached
Cidara Therapeutics (CDTX) is a small-cap biotech with 38 employees and a market cap of approximately $6.96B, focused on antifungal therapies. Its lead asset, Rezafungin for Injection, is in Phase 3 development for candidemia, with two earlier-stage assets (CD101 Vaginal Gel and CD101) in Phase 2 for candidal indications. Financial data reveals persistent net losses averaging ~$67M annually from 2020–2024, with a sharp revenue drop from $64M in 2023 to $1M in 2024.
The catalyst path
No upcoming catalysts in our calendar.
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Rezafungin for Injection | Phase 3 | Candidemia |
| CD101 Vaginal Gel (3%) | Phase 2 | Candidiasis, Vulvovaginal |
| CD101 | Phase 2 | Candidemia |
Price & technical context
3-month
+129.5%
6-month
+338.8%
12-month
+710.9%
52-wk range
$16.43–$221.38
vs 50-day MA
+19.6%
vs 200-day MA
+164.6%
Realized vol
123.3%
Max drawdown
-56.2%
Daily closes through 2026-01-06. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for CDTX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.